Degradation of C1-inhibitor by plasmin: Implications for the control of inflammatory processes

Molecular Medicine

Volumn 3, Issue 6, 1997, Pages 385-396

  Wallace, Eleanor M ^a   Perkins, Stephen J ^b   Sim, Robert B ^c   Willis, Anthony C ^c   Feighery, Con ^a   Jackson, John ^a,d  

^a ST JAMES S HOSPITAL   (Ireland)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; PLASMIN; PLASMINOGEN;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CONTROLLED STUDY; DEGRADATION; HUMAN; HUMAN TISSUE; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030757454     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401685     Document Type: Article

References (39)

1. Rubin E, Farber JL (eds). (1988) Pathology. J. B. Lippincott, Philadelphia, pp. 34-1393.
2. Bode W, Huber R. (1992) Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 204: 433-451.
3. Travis J, Salvesen G. (1983) Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52: 655-709.
4. Carrell RW, Boswell DR. (1986) Serpins: The superfamily of plasma protease inhibitors. In: Barrett AJ, Salvesen G (eds). Proteinase Inhibitors. Research Monographs in Cell and Tissue Physiology, Vol. 12. Elsevier, Amsterdam, pp. 403-420.
5. Davis III, AE. (1988) Cl-Inhibitor and hereditary angioneurotic edema. Annu. Rev. Immunol. 6: 595-628.
6. Heidtmann H, Travis J. (1986) Human α-1-proteinase inhibitor. In: Barrett AJ, Salvesen G (eds). Proteinase Inhibitors. Research Monographs in Cell and Tissue Physiology Vol. 12. Elsevier, Amsterdam, pp. 441-455.
7. Miura O, Hirosawa S, Kato A, Aoki N. (1989) Molecular basis for congenital deficiency of α-2-plasmin inhibitor. J. Clin. Invest. 83: 1598-1604.
8. Beresford CH, Owen MC. (1990) Antithrombin III. Int. J. Biochem. 22: 121-128.
9. Sellar GC, Whitehead AS. (1993) The acute phase response and major acute phase proteins in early host defense. J. Biomed. Sci. 4: 1-9.
10. Kerr MA, Yeung-Laiwah AAC. (1986) Cl-inhibitor deficiency and angio-oedema. In: Whaley K (ed). Complement in Health and Disease. MTP Press, Lancaster, U.K., pp. 53-78.
11. Gaffney PJ. (1993) Fibrinolysis. In: Bloom AL, Thomas DP (eds). Haemostasis and Thrombosis. Churchill Livingstone, Edinburgh, pp. 223-244.
12. Harpel PC, Cooper NR. (1975) Studies on human plasma Cl inactivator-enzyme interactions. J. Clin. Invest. 55: 593-604.
13. Donaldson VH, Harrison RA, Rosen FS, Bing DH, Kindness G, Canar J, Wagner CJ, Awad S. (1985) Variability in purified dysfunc tional Cl-inhibitor proteins from patients with hereditary angioneurotic edema. J. Clin. Invest. 75: 124-132.
14. Jackson J, Sim RB, Whaley K, Feighery C. (1989) Autoantibody facilitated cleavage of Cl-Inhibitor in autoimmune angioedema. J. Clin. Invest. 83: 698-707.
15. Wallace EM, Feighery C, Jackson J. (1996) A solid phase antibody capture assay for the measurement of Cl-inhibitor consumption in vivo. Scand. J. Clin. Lab. Invest. 56: 1-9.
16. Laemmli UK. (1970) Cleavage of structural proteins during the assembly of the head bacteriophage T4. Nature 227: 680-683.
17. Sim RB, Reboul A. (1981) Preparation and properties of human Cl-inhibitor. Methods Enzymol. 80: 43-54.
18. Harrison RA. (1983) Human Cl-inhibitor: Improved isolation and preliminary structural characterisation. Biochemistry 22: 5001-5007.
19. Deutsch DG, Mertz ET. (1970) Plasminogen: Purification from human plasma by affinity chromatography. Science 170: 1095-1096.
20. Perkins SJ, Smith FS, Amatayakul S, Ashford D, Rademacher TW, Dwek RA, Lachmann PJ, Harrison RA. (1990) The two domain structure of the native and reaction centre cleaved forms of Cl-inhibitor of human complement by neutron scattering. J. Mol Biol. 214: 751-763.
21. Arlaud GJ, Sim RB, Duplaa AM, Colomb MG. (1979) Differential elution of Clq, Clr and Cls from human Cl bound to immune aggregates. Use in the rapid purification of Cl subcomponents. Mol. Immunol. 16: 445-450.
22. Perkins SJ. (1993) Three-dimensional structure and molecular modeling of Cl-inhibitor. Behring Inst. Mitteil. 93: 63-68.
23. Laskowski RA, McArthur MW, Moss DS, Thornton JM. (1993) PROCHECK - A program to check the stereochemical quality of protein structures. J. Appl. Crystall. 26: 283-291.
24. Lee B, Richards FM. (1971) The interpretation of protein structures: Estimation of static accessibility. J. Mol. Biol. 55: 379-400.
25. Bock SC, Skriver K, Nielson E, Thogersen H-C, Wiman B, Donaldson VH, Eddy RL, Marrinan J, Radziejewska E, Huber R, Shows TB, Magnusson S. (1986) Human Cl-inhibitor: Primary structure, cDNA cloning, and chromosomal localisation. Biochemistry 25: 4292-4301.
26. Harris E. (1993) Etiology and pathogenesis of rheumatoid arthritis. In: Kelly H, Harris E, Ruddy S, Sledge C (eds). Textbook of Rheumatology. W. B. Saunders, London, pp. 883-873.
27. Salvesen GS, Catanese JJ, Kress LF, Travis J. (1985) Primary structure of the reactive site of human Cl-inhibitor. J. Biol. Chem. 260: 2432-2436.
28. Patson PA, Gettins P, Beecham J, Schapira M. (1991) Mechanism of serpin action: That Cl inhibitor functions as a suicide substrate. Biochemistry 30: 8876-8882.
29. 1H-NMR and Fourier transform infra-red spectroscopy. J. Mol. Biol. 228: 1235-1254.
30. 2-plasmin inhibitor and Cl inactivator by human polymorphonuclear leukocyte elastase. J. Biol. Chem. 257: 9849-9854.
31. Knauper V, Triebel S, Reinke H, Tschesche H. (1991) Inactivation of human plasma Cl-inhibitor by human PMN leucocyte matrix metalloproteinases. FEBS Lett. 290: 99-102.
32. Schoenberger OL, Sprows JF, Schlechter NM, Cooperman BS, Rubin H. (1989) Limited proteolysis of Cl-inhibitor by chymotrypsin-like proteinases. FEBS Lett. 259: 165-167.
33. Guerrero R, Velasco F, Rodriguez M, Lopez A, Rojas R, Alvarez MA, Villabis R, Rubio V, Torres A, del Castillo D. (1993) Endotoxin-induced pulmonary dysfunction is prevented by Cl-esterase inhibitor. J. Clin. Invest. 91: 2754-2760.
34. Dickneite G, Seiffge D. (1996) Efficacy of Cl-inhibitor on capillary leakage and septic shock in the rat. In: Faist E, Baue AE, Schildberg FW (eds). Immune Consequences of Trauma, Shock and Sepsis. Mechanistic and Therapeutic Approaches. Pabst Science Publications, Berlin, pp. 44-50.
35. Kitchens C. (1995) Disseminated intravascular coagulation. Curr. Opin. Haematol. 2: 402-406.
36. Cugno M, Nuijens J, Hack E, Eerenberg A, Frangi D, Agostoni A, Cicardi M. (1990) Plasma levels of Cl inhibitor complexes and cleaved Cl inhibitor in patients with hereditary angioneurotic edema. J. Clin. Invest. 85: 1215-1220.
37. Cugno M, Hack CE, deBoer JP, Eerenberg JM, Agostoni A, Cicardi M. (1993) Generation of plasmin during acute attacks of hereditary angioedema. J. Lab. Clin. Med. 121: 38-43.
38. Cugno M, Cicardi M, Agostoni A. (1994) Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: A rationale for prophylactic use of tranexamic acid. J. Allergy Clin. Immunol. 93: 870-876.
39. Madalinski K, Sabbouh K, Chorazykiewicz M, Gregorek H. (1991) Cl-inhibitor defect as an example of deficiency disease. Immunol. Invest. 20: 133-141.